Back

LCZ696 and the use of biomarkers.

22 May 2016 (17:08 - 17:21)
Organised by:
Congress Presentation Part of: What a busy clinician needs to know about LCZ696 for heart failure Miscellaneous HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Professor Scott Solomon

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

6 More presentations in this session

Presentation thumbnail
The drug and the PARADIGM-HF trial.
Professor J. McMurray (Glasgow, GB)
Slides Video
Presentation thumbnail
What was it approved for in Europe – The EMA recommendations.
Doctor K. Prasad (London, GB)
Slides Video
Presentation thumbnail
What the 2016 guidelines say.
Professor P. Ponikowski (Wroclaw, PL)
Slides Video
Presentation thumbnail
LCZ696 and Alzheimers?
Professor A. Zeiher (Frankfurt, DE)
Slides Video
Presentation thumbnail
LCZ696 and drug-drug interactions?
Professor G. Rosano (London, GB)

Access the full session

Session thumbnail
What a busy clinician needs to know about LCZ696 for heart failure

The Event

Event poster

HEART FAILURE 2016

22 May 2016 17:08 CET
You may be interested in
thumbnail
Congress Presentation
Investigation of biomarker response to SGLT2 Inhibition in heart failure (SiN-HF)
30 August 2025
thumbnail
Webinar
ACVC Biomarker Talk Series - Screening the general population - a role for cardiac biomarkers?
13 July 2022
thumbnail
Congress Presentation
Lipidomic, plasma and flow cytometry signatures enhance the classification of patients with advanced CVD and CKM syndrome
1 September 2025
thumbnail
Congress Presentation
Olmesartan improves left ventricular hypertrophy in patients with hypertension and type 2 diabetes with low angiotensin-(1-7) blood levels
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources